GlycoMimetics is a clinical-stage biotechnology company focused on improving the lives of people living with cancer and inflammatory diseases by utilizing the inhibition of carbohydrate interactions that occur on the surface of cells. Co. is developing uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, a hematologic cancer, and potentially other hematologic cancers. Co. has designed an antagonist of E-selectin, GMI-1687, that could be suitable for subcutaneous administration. Co. has also selected a primary galectin drug candidate, GMI-2093, for evaluation in preclinical studies.